tbuckley/cabot-search huggingface dataset:
Evaluation of the Response to Breast Cancer Neoadjuvant Chemotherapy Using 18F-FDG Positron Emission Mammography Compared With Whole-Body 18F-FDG PET
Authors: Mutsumi Noritake, Kazutaka Narui, Tomohiro Kaneta, Sadatoshi Sugae, Kentaro Sakamaki, Tomio Inoue, Takashi Ishikawa
Journal: Clinical Nuclear Medicine (2017)

Purpose The aim of this study was to assess therapeutic response to breast cancer neoadjuvant chemotherapy (NAC) by 18F-FDG positron emission mammography (PEM) compared with that to whole-body 18F-FDG PET (WBPET). Methods Twenty patients underwent WBPET and PEM 3 times: the first time was before NAC, the second time was after 2 courses of NAC, and the third time was after all courses of NAC. A pathological complete response (pCR) was defined as no evidence of residual invasive cancer with or without ductal carcinoma in situ. The relationships between each modality's SUVmax and pathological response were evaluated. Results Nine patients achieved a pCR, whereas the other 11 patients had a non-pCR. The SUVmax of WBPET after 2 courses of NAC was significantly lower in the pCR group than in the non-pCR group (1.4 ± 0.4 vs 2.7 ± 2.1, P = 0.0334). There were no significant differences in the SUVmax of PEM (ie, PEM uptake value [PUV]) between the groups. The SUVmax of WBPET (area under the ROC curve [AUC] = 0.761) was superior to the PUVmax (AUC, 0.648) for predicting non-pCR at the interim time point. After all courses of chemotherapy, there were no significant differences between the groups in the SUVmax of WBPET; however, PUVmax was significantly lower in the pCR group than in the non-pCR group (1.0 ± 0.2 vs 2.5 ± 2.7, P = 0.0351). After NAC, the PUVmax (AUC, 0.796) was superior to the SUVmax of WBPET (AUC, 0.671). Conclusions There proved to be no apparent superiority of PEM in predicting pCR at the interim time point. Positron emission mammography had greater diagnostic capability for detecting residual cancer after all courses of NAC.
Similar Survival after Bone Marrow Versus Peripheral Blood Stem Cell Transplantation from Matched Unrelated Donors in Children with Hematologic Malignancies.
Authors: Roland Meisel, Hans-Juergen Laws, Stephan Balzer, Benedikt Bernbeck, Christof Kramm, Stephan Schoenberger, Kumar Sinha, Anja Troeger, Peter Wernet, Ulrich Goebel, Juergen Enczmann, Dagmar Dilloo
Journal: Blood (2005)
TCT-716 First Simultaneous Assessment of the Effects of Fish Oil Supplementation on Lipid and Thrombogenicity Profiles
Authors: Kevin Bliden, Anand Singla, Udaya Tantry, Peter Toth, Young-Hoon Jeong, Ali Tabrizchi, Denny Mathew, William Muse, Gordon Ens, Paul Gurbel
Journal: Journal of the American College of Cardiology (2012)
Purified Murine Hematopoietic Stem Cells Contribute to the Generation of Cardiomyocytes Via Cell Fusion.
Authors: Mitsuhiro Fukata, Fumihiko Ishikawa, Hideki Shimazu, Hiroyuki Ito, Kazuya Shimoda, Koichi Akashi, Leonard D. Shultz, Mine Harada
Journal: Blood (2005)
Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.
Authors: Filippo G. De Braud, Lorenzo Pilla, Monica Niger, Silvia Damian, Benedetta Bardazza, Antonia Martinetti, Giuseppe Pelosi, Giovanna Marrapese, Laura Palmeri, Giulio Cerea, Emanuele Valtorta, Silvio Veronese, Andrea Sartore-Bianchi, Elena Ardini, Marcella Martignoni, Arturo Galvani, Paul Pearson, David Luo, James L. Freddo, Salvatore Siena
Journal: Journal of Clinical Oncology (2014)

2502 Background: RXDX-101 is an oral small molecule inhibitor of TrkA, TrkB and TrkC, as well as ROS1 and ALK, with high potency and selectivity. RXDX-101 has demonstrated potent pharmacological activity in preclinical studies and has the potential to be first-in-class against the Trk family of kinases. This study aims to determine the MTD, PD, PK, and anti-tumor activity in patients with advanced cancer with applicable molecular alterations. Methods: Phase 1 dose escalation in patients with advanced solid tumors. Patients were treated with RXDX-101, dosed orally once each day in a 4 day on, 3 day off schedule for 3 weeks, followed by a 7 day rest period, in continuous 28-day cycles. A minimum of 3 patients were enrolled at each dose level. Endpoints include safety, PK, and tumor response by RECIST. Results: 17 patients have been treated at 5 dose levels (100, 200, 400, 800, and 1200 mg/m2). RXDX-101 has been well tolerated to date; the MTD has not been reached in this trial. The most common AEs (all grade 1-2), considered possibly treatment-related, included paresthesias, nausea, dysgeusia, and diarrhea. No treatment related grade 3/4 AEs or SAEs were observed; one patient had grade 3 dyspnea considered to be disease-related. No DLTs seen to date. A patient with neuroblastoma (ALK+) has a PR and is in cycle 13. Two patients have prolonged stabilization of their disease and remain on treatment; a patient with NSCLC (ALK+) in cycle 11, and a patient with pancreatic cancer (ROS1+) in cycle 8. PK analysis shows maximum concentrations of RXDX-101 were generally achieved within 2 to 4 hours following dosing. Despite a degree of variability, RXDX-101 exposure (Cmax and AUC) increased with dose, with minimal accumulation following multiple doses. Average terminal half-life was ~21 hours across the dose range of 100 to 400 mg/m2/day, but increased to 32 hours in patients treated with 800 mg/m2/day; steady state was reached within 4-days. Conclusions: RXDX-101 has been well tolerated in patients with advanced solid tumors. Continued clinical development is supported by the tolerability and early evidence of antitumor activity in patients with relevant molecular alterations.
Multiple Complete Responses in a Phase 1 Dose-Escalation Study of the Antibody-Drug Conjugate SGN-35 in Patients with Relapsed or Refractory CD30-Positive Lymphomas.
Authors: Anas Younes, Andres Forero-Torres, Nancy L. Bartlett, John P. Leonard, Carmel Lynch, Dana A. Kennedy, Eric Sievers
Journal: Blood (2008)
Allogeneic Cytokine-Induced Killer Cells Eliminate Host Dendritic Cells Due To The Enhanced Killing Activity By IFN-Gamma, Leading To Less Graft-Versus-Host Disease
Authors: Shintaro Mase, Toshihiro Fujiki, Rie Kuroda, Raita Araki, Hideaki Maeba, Shoichi Koizumi, Akihiro Yachie, Ryosei Nishimura
Journal: Blood (2013)
Strategies for Preventing Folate-Related Neural Tube Defects
Authors: James L. Mills
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Knockdown of the Transcription Factor PU.1 Causes Characteristic Transcriptional Changes in Hematopoietic Stem Cells Prior to Leukemic Transformation.
Authors: Ulrich Steidl, Frank Rosenbauer, Xuesong Gu, Bronwyn Owens, Steffen Klippel, Katharina Wagner, Manuel Aivado, Towia A. Libermann, Daniel G. Tenen
Journal: Blood (2004)
Anti-Heparanase Therapy in Combination with Conventional Chemotherapy Potently Inhibits Multiple Myeloma Growth in Vivo
Authors: Joseph P. Ritchie, Annamaria Naggi, Giangiacomo Torri, Benito Casu, Claudio Pisano, Paolo Carminati, Israel Vlodavsky, Ralph D. Sanderson, Yang Yang
Journal: Blood (2008)
Duration of Initial Admission and Subsequent Readmission in the First 100 Days Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation.
Authors: Moez Dungarwalla, Joy Brennan, Samar Kulkarni, Radovan Saso, Bronwen Shaw, Treleaven G. Jennifer, Dearden E. Claire, Morgan J. Gareth, Ethell E. Mark, Potter N. Mike
Journal: Blood (2007)
Membrane-Depolarizing Channel Blockers Induce Selective Glioma Cell Death by Impairing Nutrient Transport and Unfolded Protein/Amino Acid Responses
Authors: Mia Niklasson, Gianluca Maddalo, Zuzana Sramkova, Ercan Mutlu, Shimei Wee, Petra Sekyrova, Linnéa Schmidt, Nicolas Fritz, Ivar Dehnisch, Gregorios Kyriatzis, Michaela Krafcikova, Brittany B. Carson, Jennifer M. Feenstra, Voichita D. Marinescu, Anna Segerman, Martin Haraldsson, Anna-Lena Gustavsson, Lars G.J. Hammarström, Annika Jenmalm Jensen, Lene Uhrbom, A.F. Maarten Altelaar, Sten Linnarsson, Per Uhlén, Lukas Trantirek, C. Theresa Vincent, Sven Nelander, Per Øyvind Enger, Michael Andäng
Journal: Cancer Research (2017)

Glioma-initiating cells (GIC) are considered the underlying cause of recurrences of aggressive glioblastomas, replenishing the tumor population and undermining the efficacy of conventional chemotherapy. Here we report the discovery that inhibiting T-type voltage-gated Ca2+ and KCa channels can effectively induce selective cell death of GIC and increase host survival in an orthotopic mouse model of human glioma. At present, the precise cellular pathways affected by the drugs affecting these channels are unknown. However, using cell-based assays and integrated proteomics, phosphoproteomics, and transcriptomics analyses, we identified the downstream signaling events these drugs affect. Changes in plasma membrane depolarization and elevated intracellular Na+, which compromised Na+-dependent nutrient transport, were documented. Deficits in nutrient deficit acted in turn to trigger the unfolded protein response and the amino acid response, leading ultimately to nutrient starvation and GIC cell death. Our results suggest new therapeutic targets to attack aggressive gliomas. Cancer Res; 77(7); 1741-52. ©2017 AACR.
Development and characterization of nifedipine-amino methacrylate copolymer solid dispersion powders with various adsorbents
Authors: Yotsanan Weerapol, Sontaya Limmatvapirat, Jurairat Nunthanid, Srisuda Konthong, Supakij Suttiruengwong, Pornsak Sriamornsak
Journal: Asian Journal of Pharmaceutical Sciences (2017)

Solid dispersions of nifedipine (NDP), a poorly water-soluble drug, and amino methacrylate copolymer (AMCP) with aid of adsorbent, that is, fumed silica, talcum, calcium carbonate, titanium dioxide, and mesoporous silica from rice husks (SRH), were prepared by solvent method. The physicochemical properties of solid dispersions, compared to their physical mixtures, were determined using powder X-ray diffractometry (PXRD) and differential scanning calorimetry (DSC). The surface morphology of the prepared solid dispersions was examined by scanning electron microscopy (SEM). The dissolution of NDP from solid dispersions was compared to NDP powders. The effect of adsorbent type on NDP dissolution was also examined. The dissolution of NDP increased with the ratio of NDP:AMCP:adsorbent of 1:4:1 when compared to the other formulations. As indicated from PXRD patterns, DSC thermograms and SEM images, NDP was molecularly dispersed within polymer carrier or in an amorphous form, which confirmed the better dissolution of solid dispersions. Solid dispersions containing SRH provided the highest NDP dissolution, due to a porous nature of SRH, allowing dissolved drug to fill in the pores and consequently dissolve in the medium. The results suggested that solid dispersions containing adsorbents (SRH in particular) demonstrated improved dissolution of poorly water-soluble drug when compared to NDP powder.
Lung Cancer Risk Prediction Model Incorporating Lung Function: Development and Validation in the UK Biobank Prospective Cohort Study
Authors: David C. Muller, Mattias Johansson, Paul Brennan
Journal: Journal of Clinical Oncology (2017)

Purpose Several lung cancer risk prediction models have been developed, but none to date have assessed the predictive ability of lung function in a population-based cohort. We sought to develop and internally validate a model incorporating lung function using data from the UK Biobank prospective cohort study. Methods This analysis included 502,321 participants without a previous diagnosis of lung cancer, predominantly between 40 and 70 years of age. We used flexible parametric survival models to estimate the 2-year probability of lung cancer, accounting for the competing risk of death. Models included predictors previously shown to be associated with lung cancer risk, including sex, variables related to smoking history and nicotine addiction, medical history, family history of lung cancer, and lung function (forced expiratory volume in 1 second [FEV1]). Results During accumulated follow-up of 1,469,518 person-years, there were 738 lung cancer diagnoses. A model incorporating all predictors had excellent discrimination (concordance (c)-statistic [95% CI] = 0.85 [0.82 to 0.87]). Internal validation suggested that the model will discriminate well when applied to new data (optimism-corrected c-statistic = 0.84). The full model, including FEV1, also had modestly superior discriminatory power than one that was designed solely on the basis of questionnaire variables (c-statistic = 0.84 [0.82 to 0.86]; optimism-corrected c-statistic = 0.83; p FEV1 = 3.4 × 10 −13 ). The full model had better discrimination than standard lung cancer screening eligibility criteria (c-statistic = 0.66 [0.64 to 0.69]). Conclusion A risk prediction model that includes lung function has strong predictive ability, which could improve eligibility criteria for lung cancer screening programs.
High Proportions of CD4+CD25hi T Cells Pretransplant Correlate with Worse Overall Survival after Stem Cell Transplant.
Authors: Adria Prieto-Hinojosa, J. Alejandro Madrigal, Bronwen E. Shaw, Neema P. Mayor, Stephen G.E. Marsh, Paul J. Travers, Rafael F. Duarte
Journal: Blood (2006)
Reduced-Intensity Conditioning (RIC) with Busulfan, Fludarabine and Campath-1H Is Complicated by a High Rate of Graft Failure and Severe Viral Complications in Patients with CLL.
Authors: Johannes Schetelig, Martin Bornhaeuser, Christian Thiede, Brigitte Mohr, Uta Oelschlaegel, Gabriele Geissler, Gabi Prange, Johannes Mohm, Christoph Roellig, Thomas Illmer, Alexander Kiani, Gerhard Ehninger, Wolfgang Siegert
Journal: Blood (2004)
Impact of Complete Kariotypic Remission (CKR) and Sokal Risk on Overall Survival in Chronic Myelogenous Leukemia (CML) Patients: A Monocentric Experience.
Authors: Lorenzo Falchi, Monica Schippa, Debora Luzi, Rita Emili, Viola Festuccia, Emilia Giugliano, Carmela Ardisia, Annamaria Rauco, Roberta Pace, Emilio Donti, Anna Marina Liberati
Journal: Blood (2006)
Optimizing Anti-Thymocyte Globulin Dosing Based on Recipient Absolute Lymphocyte Count after Unrelated Allogeneic Hematopoietic Cell Transplant
Authors: Vanessa E Kennedy, Heidi Chen, Bipin N. Savani, John P. Greer, Adetola A. Kassim, Brian G Engelhardt, Stacey A. Goodman, Salyka M. Sengsayadeth, Wichai Chinratanalab, Madan H. Jagasia
Journal: Blood (2015)
John Hunter—Transcending Surgical Boundaries
Authors: Vincent M. Hsu, Adam S. Aldahan, Vidhi V. Shah, Stephanie Mlacker, Keyvan Nouri
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Woman dies after infection with bacteria resistant to all antibiotics available in US
Authors: Michael McCarthy
Journal: BMJ (2017)

A woman in the US died of septic shock last year after becoming infected with carbapenem resistant Enterobacteriaceae (CRE) that were resistant to all antimicrobial drugs available in the US.

The bacterium, a Klebsiella pneumoniae , was found to be resistant to 26 antibiotics, including all aminoglycosides and polymyxins tested, and intermediately resistant to tigecycline.

The case was described in the 13 January issue of the US Centers for Disease Control and Prevention’s (CDC) Morbidity and Mortality Weekly Report .1 It involved a woman in her 70s living in Washoe County, Nevada, who had lived in India for an extended …
Evaluation of Parvovirus B19 and Herpesvirus-6 Serology in Brazilian Children with Common B Cell Precursor Acute Lymphoblastic Leukemia
Authors: Fernanda A Silva, Gisele M Vasconcelos, Synara NS Cordeiro, Mariana Sant’Ana, Silvia Maia Farias de Carvalho, Maria S. Pombo-de-Oliveira
Journal: Blood (2008)
Lymphangioleiomyomatosis: A Monogenic Model of Malignancy
Authors: Vera P. Krymskaya, Francis X. McCormack
Journal: Annual Review of Medicine (2017)

Lymphangioleiomyomatosis (LAM) is a rare, low-grade, metastasizing neoplasm that arises from an unknown source, spreads via the lymphatics, and targets the lungs. All pulmonary structures become infiltrated with benign-appearing spindle and epithelioid cells (LAM cells) that express smooth-muscle and melanocyte-lineage markers, harbor mTOR-activating mutations in tuberous sclerosis complex (TSC) genes, and recruit abundant stromal cells. Elaboration of lymphangiogenic growth factors and matrix remodeling enzymes by LAM cells enables their access to lymphatic channels and likely drives the cystic lung remodeling that often culminates in respiratory failure. Dysregulated cellular signaling results in a shift from oxidative phosphorylation to glycolysis as the preferred mode of energy generation, to allow for the accumulation of biomass required for cell growth and tolerance of nutrient-poor, anaerobic environments. Symptomatic LAM occurs almost exclusively in females after menarche, highlighting the central but as yet poorly understood role for sex-restricted anatomical structures and/or hormones in disease pathogenesis. LAM is an elegant model of malignancy because biallelic mutations at a single genetic locus confer all features that define cancer upon the LAM cell—metabolic reprogramming and proliferative signals that drive uncontrolled growth and inappropriate migration and invasion, the capacity to exploit the lymphatic circulation as a vehicle for metastasis and access to the lungs, and destruction of remote tissues. The direct benefit of the study of this rare disease has been the rapid identification of an effective FDA-approved therapy, and the collateral benefits have included elucidation of the pivotal roles of mTOR signaling in the regulation of cellular metabolism and the pathogenesis of cancer.
GIMEMA-AIEOP AIDA Protocols for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) In Children: Analysis of 247 Patients Enrolled In Two Sequential Italian Multicenter Trials
Authors: Anna Maria Testi, Robin Foa, Gabriella Tomei, Francesco Lo Coco, Andrea Biondi, Andrea Pession, Daniela Diverio, Marco Vignetti, Giuseppe Basso, Franco Locatelli, Carmelo Rizzari, Giuseppe Menna, Maria Luisa Moleti, Nicola Santoro, Giuseppe Fioritoni, Riccardo Masetti, Franco Mandelli
Journal: Blood (2010)
Pharmacokinetic and biological study of erlotinib in children as monotherapy for refractory brain tumors or with radiation for newly diagnosed brain stem gliomas
Authors: B. Geoerger, D. Hargrave, F. Thomas, F. Andreiuolo, P. Varlet, D. Frappaz, F. Doz, R. Riccardi, T. Jaspan, G. Vassal
Journal: Journal of Clinical Oncology (2009)

10019 Background: This multicenter phase I study was designed to determine the recommended dose (RD) of erlotinib, a small-molecule EGFR TKI, in patients ≤ 21 years as monotherapy or in combination with radiation therapy (RT). Methods: Group 1 included patients with brain tumors refractory to or relapsing after conventional therapy; receiving erlotinib alone. Group 2 included newly diagnosed patients with brain stem gliomas, who received RT (54Gy) and erlotinib. Conventional 3+3 dose escalation was used for Group 1; a continual reassessment method for Group 2. Four dose levels were planned: 75, 100, 125 and 150 mg/m 2 /day. Results: A total of 51 patients were enrolled (30 in Group 1; 21 in Group 2); 50 received treatment. Median age was 10 and 6 years, respectively. The RD of erlotinib was 125 mg/m 2 /day as monotherapy or in combination with RT. 203 adverse events in 44 patients were possibly treatment-related; 188 were G1/2; 9 G3, 2 G4, and 4 G5. Dermatologic and neurologic symptoms were most common; intratumoral hemorrhage was noted in 4 patients. In Group 1, 8 patients (27.6%) had stable disease, 2 with 45% tumor regression. In Group 2, 3 patients (14%) had partial response and 8 (38%) were stabilized; median OS was 12 months. Pharmacokinetic data of 46 patients were analyzed; patients’ weight and erlotinib clearance (CL) were significantly correlated. Mean (± SD) apparent CL and volume of distribution for erlotinib were 143.7 mL/h/kg (± 66.3) and 3.5 L/kg (± 3.0), respectively, and were independent of dose level. Mean half-life for erlotinib was 20.4 hours. Biomarker analyses on archived tumor or biopsy tissue prior to study entry for newly diagnosed brain stem glioma found 18/37 tumors tested were EGFR IHC+; 16/37 and 23/36 were pAKT+ and pMAPK+, respectively. High EGFR expression was more common in supratentorial gliomas; PTEN loss was most common in brain stem glioma (15/19) and was not observed in ependymomas. Conclusions: Erlotinib 125 mg/m 2 /day has an acceptable tolerability profile in pediatric patients with brain tumors, and can be safely combined with RT. Further studies are required to define the efficacy of this treatment approach and to establish the impact of biomarkers on outcomes in pediatric glial tumors. No significant financial relationships to disclose.
Re: Amar U. Kishan, Talha Shaikh, Pin-Chieh Wang, et al. Clinical Outcomes for Patients with Gleason Score 9–10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol 2017;71:766–73
Authors: Thomas Van den Broeck, R. Jeffrey Karnes, Steven Joniau
Journal: European Urology (2017)
Transcranial Doppler (TCD) Ultrasonography in Infants with Sickle Cell Anemia: Baseline Data from the BABY HUG Trial.
Authors: Winfred Wang, Renee C Rees, Scott T. Miller, R. Clark Brown, James F. Casella, Rathi V. Iyer, Ram V. Kalpathi, Judy Luden, Zora R. Rogers, Courtney Thornberg, Robert J. Adams, Steven Pavlakis
Journal: Blood (2008)